Synthesis, biological evaluation, and computational studies of N-benzyl pyridinium-curcumin derivatives as potent AChE inhibitors with antioxidant activity

J Enzyme Inhib Med Chem. 2023 Dec;38(1):2281264. doi: 10.1080/14756366.2023.2281264. Epub 2023 Nov 20.

Abstract

A library of N-benzylpyridinium-based compounds, 7a-j and 8a-j, was designed and synthesised as potential acetylcholinesterase) AChE (inhibitors. An in vitro assay for the synthesised compounds showed that most compounds had significant AChE inhibitory activities at the nanomolar and submicromolar levels. The benzyl (8a) and fluoro (8b) derivatives were the most active, with IC50 values ≤56 nM. Compound 7f, which had a benzyl moiety, showed the highest potency among all the target compounds, with an IC50 value of 7.5 ± 0.19 nM against AChE, which was higher than that of the activities of tacrine (IC50 = 30 ± 0.2 nM) and donepezil (IC50 = 14 ± 0.12 nM). Compounds with vanillin moieties exhibited antioxidant activity. Among the tested compounds, four derivatives (7f, 7 g, 8f, and 8 g) exhibited superior AChE inhibitory activity, with Ki values of 6-16 nM, which were potent in the same range as the approved drug, donepezil. These compounds showed moderate antioxidant activities, as indicated by the results of the ABTS assay.

Keywords: Acetylcholinesterase inhibitors; Alzheimer’s disease; antioxidants; docking study; pyridinium; synthesis.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease*
  • Antioxidants / pharmacology
  • Cholinesterase Inhibitors / pharmacology
  • Curcumin*
  • Donepezil
  • Humans
  • Molecular Docking Simulation
  • Pain
  • Structure-Activity Relationship

Substances

  • Donepezil
  • Cholinesterase Inhibitors
  • Antioxidants
  • Curcumin
  • Acetylcholinesterase

Grants and funding

The authors gratefully acknowledge the financial support from GJU (project: SAMS-01/2018) for conducting this work.